Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.

Scientific reports - 29 Oct 2024

Abdel-Wahed Marwa A, Sabbour Ghada Sadek, Hamed Amira I, El Kady Mohammed Sabry, Mohammed Shaimaa Khalil, Shaaban Menat Allah Ali Mahmoud

Abstract excerpt

Breast cancer is considered a multifactorial disease, with genetic factors playing an important role in diagnosis and treatment. FCGR3A encodes the receptor for the Fc portion of immunoglobulin G that has been linked to the trastuzumab response. Our study aimed to investigate the association of FCGR3A-V158F gene polymorphism with breast cancer and to evaluate the impact of FCGR3A-V158F gene polymorphism on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Case-Control Studies

Share to Receptor, ErbB-2

Share to Receptors, IgG

Share to Trastuzumab

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39472454
DOI: 10.1038/s41598-024-76024-6
PMCID: PMC11522560

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FCGR3A V158F gene polymorphism and trastuzumab response in HER2-positive breast cancer patients.PMID 39472454Read ↗

The FCGR3A polymorphism predicts the response to rituximab-based therapy in patients with non-Hodgkin lymphoma: a meta-analysis.Semantic proximity Read ↗

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Semantic proximity Read ↗

FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population.Semantic proximity Read ↗

Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients.Semantic proximity Read ↗

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.Semantic proximity Read ↗

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.Semantic proximity Read ↗

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerSemantic proximity Read ↗

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.Semantic proximity Read ↗

Association between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.Semantic proximity Read ↗

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.Semantic proximity Read ↗

FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Effects of immunorelated gene polymorphisms on trastuzumab targeting breast cancer cellSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.